

RECEIVED  
CENTRAL FAX CENTER  
NOV 16 2004

Attorney Docket No.: 4318.234-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al. Confirmation No: 8501

Serial No.: 10/025,648 Group Art Unit: 1751

Filed: December 19, 2001 Examiner: Prouty

For: Amylase Variants

## CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Response to Request to Supply Sequence Listing
2. Sequence Listing

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Prouty, fax number (571)273-0937.

Respectfully submitted,

Date: November 16, 2004

  
Julie Tabarovsky  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

RECEIVED  
CENTRAL FAX CENTER  
NOV 16 2004

Attorney Docket No.: 4318.234-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al. Confirmation No: 8501  
Serial No.: 10/025,648 Group Art Unit: 1751  
Filed: December 19, 2001 Examiner: Prouty  
For: Amylase Variants

## RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS

Mail Stop Sequence  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


This paper is in response to Examiner's request to supply a paper copy of the Sequence Listing.

Applicants therefore attach a Sequence Listing. The computer-readable form in this application is identical with that filed in application no. 08/600,656 filed on February 13, 1996. In accordance with 37 CFR 1.821(e), please use the last filed computer readable form filed in that application as the computer readable form for the instant application. The content of the attached Sequence Listing and of the computer readable form filed in the parent application is the same. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 16, 2004

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097